Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27868879 | 0.84 | BACE1 (0.53) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL5057022 | 0.83 | AHR (0.50) | AHRCYP2A6FAAHKDM4EGPR84 | |
| SCHEMBL9027101 | 0.81 | BACE1 (0.50) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL5470166 | 0.81 | BACE1 (0.52) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL13978582 | 0.79 | AHR (0.55) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL1252105 | 0.79 | TYR (0.55) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL879350 | 0.79 | BACE1 (0.51) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL31271 | 0.79 | AHR (0.50) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL30939502 | 0.79 | AHR (0.55) | AHRCMA1TYRBACE1NLRP3 | |
| SCHEMBL5390737 | 0.79 | AHR (0.55) | AHRCMA1TYRBACE1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | claimed |
| EP-3952874-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | Prelude Therapeutics, Incorporated (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3939986-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2022-01-19 | — | — | EP | claimed |
| WO-2020206289-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-10-08 | — | — | WO | claimed |
| CN-111527099-A | Selective inhibitors of protein arginine methyltransferase 5(PRMT5) | 普莱鲁德疗法有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-3665179-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2020-06-17 | — | — | EP | claimed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | claimed |
| CN-111527099-B | Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) | 普莱鲁德疗法有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117279928-A | Process for the preparation of cyclic compounds comprising N-substituted amino acid residues | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-116615411-A | Process for producing peptide compound containing N-substituted amino acid residue | 中外制药株式会社 | 2023-08-18 | — | — | CN | disclosed |
| CN-116547295-A | Method for supporting amino acid on resin for solid phase synthesis | 中外制药株式会社 | 2023-08-04 | — | — | CN | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
| CN-108358827-A | It is a kind of to treat psoriasic 2- oxo-indoles analog derivative and preparation method thereof | 日照市普达医药科技有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-104603106-B | Indole carboxamide derivatives and uses thereof | 诺华股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-105531279-A | Substituted pyrazolo-pyridinamines | Bayer Pharma AG | 2016-04-27 | — | — | CN | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | AHR 4358/4885CMA1 2219/4885TYR 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.